We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Premenstrual Dysphoric Disorder and Response to Cholecystokinin-Tetrapeptide

Jean-Michel Le Melledo, MD; Jacques Bradwejn, MD; Diana Koszycki, PhD; Daniel Bichet, MD
Arch Gen Psychiatry. 1995;52(7):605-606. doi:10.1001/archpsyc.1995.03950190087012.
Text Size: A A A
Published online


We read with interest the article by Leibenluft and colleagues1 in the October 1994 issue of the Archives, which summarized the clinical data on how menstrual cycles can influence biochemical responses to biological challenges. Although the review emphasized mood disorder studies, the authors' conclusions can be extended to biological research in panic disorder. An overlooked area in biological studies of panic disorder is the influence of menstrual cycles and premenstrual syndrome on behavioral sensitivity to panicogenic agents. In this regard, we conducted a study to compare the behavioral response of normal women with and without premenstural dysphoric disorder (PDD) to systemic administration of cholecystokinin-tetrapeptide (CCK-4), a well-validated panicogenic agent. We present herein preliminary data collected from 12 women with PDD and 13 women without PDD.

All of our subjects were screened with the Structured Clinical Interview for DSM-III-R, Non-Patient Editor2 to exclude those with Axis I disorders. The


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.